Short Interest in Invivyd, Inc. (NASDAQ:IVVD) Expands By 24.4%

Invivyd, Inc. (NASDAQ:IVVD) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 35,613,115 shares, a growth of 24.4% from the December 15th total of 28,634,579 shares. Based on an average daily volume of 5,706,265 shares, the days-to-cover ratio is currently 6.2 days. Approximately 20.5% of the company’s shares are sold short. Approximately 20.5% of the company’s shares are sold short. Based on an average daily volume of 5,706,265 shares, the days-to-cover ratio is currently 6.2 days.

Wall Street Analyst Weigh In

A number of analysts have issued reports on IVVD shares. HC Wainwright boosted their price target on shares of Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. D Boral Capital cut shares of Invivyd from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 25th. BTIG Research initiated coverage on shares of Invivyd in a report on Monday, December 22nd. They set a “buy” rating and a $10.00 target price on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. Finally, Cantor Fitzgerald started coverage on Invivyd in a research report on Monday, October 6th. They set an “overweight” rating and a $10.00 price objective on the stock. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Invivyd currently has an average rating of “Hold” and a consensus price target of $8.00.

Insider Transactions at Invivyd

In other Invivyd news, Director Kevin F. Mclaughlin acquired 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The shares were purchased at an average cost of $2.50 per share, for a total transaction of $125,000.00. Following the completion of the acquisition, the director owned 50,000 shares of the company’s stock, valued at approximately $125,000. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 25.40% of the company’s stock.

Institutional Investors Weigh In On Invivyd

Several institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new stake in shares of Invivyd in the fourth quarter valued at about $60,000. Catalyst Funds Management Pty Ltd purchased a new position in Invivyd in the second quarter valued at about $27,000. Vanguard Personalized Indexing Management LLC lifted its position in shares of Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock valued at $29,000 after acquiring an additional 28,146 shares during the period. Bank of America Corp DE boosted its stake in shares of Invivyd by 330.5% during the 3rd quarter. Bank of America Corp DE now owns 49,252 shares of the company’s stock worth $54,000 after acquiring an additional 37,811 shares in the last quarter. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of Invivyd in the 3rd quarter worth approximately $102,000. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Invivyd Trading Up 0.4%

Shares of NASDAQ IVVD traded up $0.01 during trading hours on Monday, reaching $2.45. The stock had a trading volume of 1,802,177 shares, compared to its average volume of 3,340,812. The firm has a 50-day moving average of $2.41 and a 200-day moving average of $1.60. The firm has a market cap of $571.14 million, a price-to-earnings ratio of -5.21 and a beta of 0.61. Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $3.07.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The business had revenue of $13.13 million for the quarter, compared to analysts’ expectations of $12.00 million. Invivyd had a negative return on equity of 92.97% and a negative net margin of 119.63%. On average, equities analysts predict that Invivyd will post -1.64 EPS for the current year.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.